Tredaptive

Nicotinic acid and laropiprant modified-release tablets for treating dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

PHARMACOLOGY

Tredaptive combines nicotinic acid (niacin), a lipid-lowering agent, with laropiprant, a selective antagonist of the prostaglandin D2 receptor subtype 1.1 Laropiprant has no effect on lipid levels, but simply suppresses the flushing caused by nicotinic acid.

CLINICAL STUDIES

In a 24-week trial in 1,216 patients, nicotinic acid (1g/day for four weeks, followed by 2g/day for 20 weeks) given in combination with laropiprant significantly improved lipid profiles compared with placebo and caused markedly less flushing than the same dose of nicotinic acid alone.2

In another trial, the 726 patients randomised to receive nicotinic acid (1g/day for four weeks, followed by 2g/day for 12 weeks) given in combination with laropiprant experienced significantly fewer days of flushing per week during the 16-week treatment period than the 729 patients who were randomised to receive nicotinic acid alone (0.5g/day for four weeks gradually titrated to 2g/day for the final four weeks), despite more rapid nicotinic acid titration.3

View Tredaptive drug record

REFERENCES

  1. Tredaptive Summary of Product Characteristics. July 2008.
  2. Maccubbin D, Bays H et al. Lipid-modifying efficacy and tolerability of e-r niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008: 62; 1959-70.
  3. Maccubbin D, Koren M et al. Flushing profile of e-r niacin/laropiprant versus gradually titrated niacin e-r in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009: 104; 74-81.

Further information: MSD


Read these next

Tredaptive withdrawn

MSD has withdrawn the lipid-lowering preparation Tredaptive...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.




Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.